tbuckley/cabot-search huggingface dataset:
Long-Acting Reversible Contraceptives for Adolescents
Authors: Maya Michelle Kumar
Journal: JAMA Pediatrics (2017)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Pediatrics HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Pediatrics journal
Sharing Clinical and Genomic Data on Cancer — The Need for Global Solutions
Authors: Mark Lawler, David Haussler, Lillian L Siu, Melissa A Haendel, Julie A McMurry, Bartha M Knoppers, Stephen J Chanock, Fabien Calvo, Bin T The, Guneet Walia, Ian Banks, Peter P Yu, Louis M Staudt, Charles L Sawyers
Journal: New England Journal of Medicine (2017)
Memory‐Shape Implants: Fast Setting Silk Fibroin Bioink for Bioprinting of Patient‐Specific Memory‐Shape Implants (Adv. Healthcare Mater. 22/2017)
Authors: João B. Costa, Joana Silva‐Correia, Joaquim M. Oliveira, Rui L. Reis
Journal: Advanced Healthcare Materials (2017)

A silk fibroin bioink for the production of patient-specific memory-shape implants is proposed by Joaquim M. Oliveira and co-workers in article number 1701021 using a fast setting enzymatic-based cross-linking reaction. The reproducibility and the reliability of this bioink allow the production of different scaffolds with superior mechanical performance. Its versatility gives new opportunity concerning tissue engineering approaches, in particular for the biofabrication of patient-specific memory-shape implants.
Not Your Typical ST-Elevation Myocardial Infarction
Authors: Alicia Morehead-Gee, Arun Padmanabhan, Nora Goldschlager
Journal: JAMA Internal Medicine (2017)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Internal Medicine HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Internal Medicine journal
Phase II Study of BGJ398 in Patients With FGFR-Altered Advanced Cholangiocarcinoma
Authors: Milind Javle, Maeve Lowery, Rachna T. Shroff, Karl Heinz Weiss, Christoph Springfeld, Mitesh J. Borad, Ramesh K. Ramanathan, Lipika Goyal, Saeed Sadeghi, Teresa Macarulla, Anthony El-Khoueiry, Robin Kate Kelley, Ivan Borbath, Su Pin Choo, Do-Youn Oh, Philip A. Philip, Li-Tzong Chen, Thanyanan Reungwetwattana, Eric Van Cutsem, Kun-Huei Yeh, Kristen Ciombor, Richard S. Finn, Anuradha Patel, Suman Sen, Dale Porter, Randi Isaacs, Andrew X. Zhu, Ghassan K. Abou-Alfa, Tanios Bekaii-Saab
Journal: Journal of Clinical Oncology (2017)

Purpose No standard treatment exists for patients with cholangiocarcinoma for whom first-line gemcitabine-based therapy fails. Fibroblast growth factor receptor 2 ( FGFR2) fusions/translocations are present in 13% to 17% of intrahepatic cholangiocarcinomas. BGJ398, an orally bioavailable, selective pan-FGFR kinase inhibitor, has shown preliminary clinical activity against tumors with FGFR alterations. Methods A multicenter, open-label, phase II study ( ClinicalTrials.gov identifier: NCT02150967) evaluated BGJ398 antitumor activity in patients age ≥ 18 years with advanced or metastatic cholangiocarcinoma containing FGFR2 fusions or other FGFR alterations whose disease had progressed while receiving prior therapy. Patients received BGJ398 125 mg once daily for 21 days, then 7 days off (28-day cycles). The primary end point was investigator-assessed overall response rate. Results Sixty-one patients (35 women; median age, 57 years) with FGFR2 fusion (n = 48), mutation (n = 8), or amplification (n = 3) participated. At the prespecified data cutoff (June 30, 2016), 50 patients had discontinued treatment. All responsive tumors contained FGFR2 fusions. The overall response rate was 14.8% (18.8% FGFR2 fusions only), disease control rate was 75.4% (83.3% FGFR2 fusions only), and estimated median progression-free survival was 5.8 months (95% CI, 4.3 to 7.6 months). Adverse events included hyperphosphatemia (72.1% all grade), fatigue (36.1%), stomatitis (29.5%), and alopecia (26.2%). Grade 3 or 4 treatment-related adverse events occurred in 25 patients (41%) and included hyperphosphatemia (16.4%), stomatitis (6.6%), and palmar-plantar erythrodysesthesia (4.9%). Conclusion BGJ398 is a first-in-class FGFR kinase inhibitor with manageable toxicities that shows meaningful clinical activity against chemotherapy-refractory cholangiocarcinoma containing FGFR2 fusions. This promising antitumor activity supports continued development of BGJ398 in this highly selected patient population.
The fork in the road
Authors: Robert J Sternberg
Journal: Behavioral and Brain Sciences (2017)

Abstract Machines that learn and think like people should simulate how people really think in their everyday lives. The field of artificial intelligence originally traveled down two roads, one of which emphasized abstract, idealized, rational thinking and the other, which emphasized the emotionally charged and motivationally complex situations in which people often find themselves. The roads should have converged but never did. That's too bad.
Serum matrix metalloproteinase-1 level represents disease activity as opposed to fibrosis in patients with histologically proven nonalcoholic steatohepatitis
Authors: Wataru Ando, Hiroaki Yokomori, Nobuhiro Tsutsui, Eigoro Yamanouchi, Yutaka Suzuki, Masaya Oda, Yutaka Inagaki, Katsuya Otori, Isao Okazaki
Journal: Clinical and Molecular Hepatology (2017)

Background/Aims Nonalcoholic steatohepatitis (NASH) is prevalent in both economically developed and developing countries. Twenty percent of NASH progresses to cirrhosis with/without hepatocellular carcinoma, and there is an urgent need to find biomarkers for early diagnosis and monitoring progression of the disease. Using immunohistochemical and immunoelectron microscopic examination we previously reported that expression of matrix metalloproteinase-1 (MMP-1) increased in monocytes, Kupffer cells and hepatic stellate cells in early stage NASH. The present study investigated whether serum MMP-1 levels reflect disease activity and pharmaceutical effects in NASH patients. Methods We measured the serum levels of MMPs, tissue inhibitors of metalloproteinases (TIMPs), and several cytokines/chemokines in patients with histologically proven early and advanced stages of NASH and compared them with those in healthy controls. Results Serum MMP-1 levels in stage 1 fibrosis, but not in the more advanced fibrosis stages, were significantly higher than in healthy controls (P=0.019). There was no correlation between serum MMP-1 level and fibrosis stage. Serum MMP- 1 levels in NASH patients represented disease activity estimated by serum aminotransferase values during the follow-up period. In contrast, MMP-2, MMP-9 and TIMPs did not change with disease activity. Consistent with the finding that MMP-1 is expressed predominantly in monocytes and Kupffer cells, serum levels of monocyte chemotactic protein-1 and granulocyte-colony stimulating factor were significantly increased in NASH with stage 1 fibrosis. Conclusions These results suggest that serum MMP-1 levels represent disease activity and may serve as a potential biomarker for monitoring the progression of NASH. Keywords: Nonalcoholic steatohepatitis; Matrix metalloprotease 1; Cytokines; Liver cirrhosis
Quality of life is significantly impaired in nonallergic rhinitis patients
Authors: C. L. Segboer, I. Terreehorst, A. Gevorgyan, P. W. Hellings, C. M. van Drunen, W. J. Fokkens
Journal: Allergy (2017)

In contrast to the well-known significant impairment of quality of life (QoL) in allergic rhinitis (AR), the degree of impairment in QoL in nonallergic rhinitis (NAR) remained unknown for a long time, due to a lack of a validated questionnaire to assess QoL in the NAR patient group. In this study, a validation of the mini-RQLQ questionnaire in NAR patients was performed, followed by an assessment of QoL in NAR patients compared to AR and healthy controls. Secondly, use of medication and treatment satisfaction in AR and NAR was assessed.The study was an observational cohort study in 287 AR and 160 NAR patients. Patients with symptoms of rhinitis were recruited from a tertiary care outpatient clinic of the Otorhinolaryngology Department. Allergic rhinitis (AR) was defined as one or more positive results on skin prick testing and clinically relevant symptoms of rhinitis related to their sensitization. Nonallergic rhinitis (NAR) was defined as clinically relevant symptoms of rhinitis but without positive results on skin prick testing. The mini-RQLQ was successfully validated in this study for NAR patients.Quality of life (QoL) in NAR patients was equally-and for some aspects even more-impaired compared to AR. More than half of both AR and NAR patients were unsatisfied with treatment.These results demonstrate a significant impairment in both AR and NAR patients in their QoL combined with a low treatment satisfaction, emphasizing the need for adequate treatment, especially in the NAR patient group.
Bortezomib based versus melphalan based regimen as induction chemotherapy for primary AL amyloidosis with cardiac involvement and factors predicting early mortality
Authors: V. Srinivasalu, M. Subramaniam, A. Shanmugam, A. Philip, A. Susan, R. Prabhu, M. Unni, N. Sidharthan, W. Jose, S. N V, P. Keechilat
Journal: Annals of Oncology (2017)
Peripapillary and Macular Vessel Density in Patients with Primary Open-Angle Glaucoma and Unilateral Visual Field Loss
Authors: Adeleh Yarmohammadi, Linda M. Zangwill, Patricia Isabel C. Manalastas, Nathanael J. Fuller, Alberto Diniz-Filho, Luke J. Saunders, Min Hee Suh, Kyle Hasenstab, Robert N. Weinreb
Journal: Ophthalmology (2017)
Do differences in patient-provider relationships explain racial differences in side effect burden among women with breast cancer in the pathways study?
Authors: Devon Check, Neetu Chawla, Isaac J. Ergas, Janise M. Roh, Tatjana Kolevska, Lawrence Kushi, Marilyn L. Kwan
Journal: Journal of Clinical Oncology (2017)

48 Background: Prior research suggests that black patients with cancer report a greater burden of symptoms compared to white patients. Differences in patient-provider relationships may be an underlying and modifiable factor in these observed disparities. We examined differences in side effect burden by race/ethnicity and tested the hypothesis that patient-provider communication and trust may partly explain differences in symptom burden among women with breast cancer (BC). Methods: We conducted a cross-sectional analysis of data collected from 4,505 women diagnosed with BC from 2005-2013 at Kaiser Permanente Northern California. Women were asked two months post-diagnosis how much they were bothered by treatment side effects (FACT-B). Using modified Poisson regression, we assessed the association of race/ethnicity with side effect bother, adjusting for clinical characteristics, socioeconomic status (SES), and patient-provider communication and patients’ trust in providers in a step-wise fashion. Provider communication and trust were measured using the Interpersonal Processes of Care survey and a one-item assessment of patients’ trust in providers, respectively. Results: Before adjustment, Black, Hispanic, and Asian patients were at least 75% more likely than white patients to report high (vs. low) side effect bother (p &lt; 0.0001). Bivariate associations of communication and trust with side effect bother and race/ethnicity were statistically significant. For example, patients with high (vs. low) scores for shared decision-making were more likely to be white than black (46% vs. 39%) and less likely to experience high vs. low side effect bother (10% vs. 14%, p &lt; 0.0001 for both comparisons). However, after adjusting for clinical and SES characteristics in a multivariable analysis, the addition of patient-provider communication and trust to the model did not substantially alter disparity estimates. Conclusions: In our sample, patient-provider communication did not modify racial disparities in side effect bother. Further research is needed to explore additional modifiable factors underlying potential disparities in side effect management.
Systolic Blood Pressure Increases with Time in Obese Patients and Is Predicted By Adipose Expression of the Mineralocorticoid Receptor Gene
Authors: R K Crowley, C Woods, B A Hughes, J Gray, T McCarthy, S Hughes, C H Shackleton, N Crabtree, P Nightingale, P M Stewart, J W Tomlinson
Journal: Endocrine Reviews (2014)
Abstract 20349: The Protective Effect of Estimated Training Status Against Oxidative Stress and High Blood Pressure Values in Middle-Aged and Older Women
Authors: Andre M Jacomini, Danielle S Dias, Janaina O Brito, Roberta F Silva, Atila A Trapé, Henrique L Monteiro, Susana Llesuy, Kátia De Angelis, Sandra L Amaral, Anderson S Zago
Journal: Circulation (2017)

The purpose of this study was to compare the association between pro and antioxidant activity, nitrite concentration, and blood pressure (BP) in middle-aged and older women with different levels of...
Sixty seconds on . . . the circadian rhythm
Authors: Anne Gulland
Journal: BMJ (2017)

Thank you for your interest in spreading the word about The BMJ.NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address. Username * Your Email * Send To * You are going to email the following Sixty seconds on . . . the circadian rhythm Your Personal Message CAPTCHA This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
A role for astroglia in prion diseases
Authors: Adriano Aguzzi, Yingjun Liu
Journal: The Journal of Experimental Medicine (2017)

In this issue of JEM, Krejciova et al. (https://doi.org/10.1084/jem.20161547) report that astrocytes derived from human iPSCs can replicate human CJD prions. These observations provide a new, potentially very valuable model for studying human prions in cellula and for identifying antiprion compounds that might serve as clinical candidates. Furthermore, they add to the evidence that astrocytes may not be just innocent bystanders in prion diseases.
Risk of losing remission, low disease activity or radiographic progression in case of bDMARD discontinuation or tapering in rheumatoid arthritis: systematic analysis of the literature and meta-analysis
Authors: Sophie Henaux, Adeline Ruyssen-Witrand, Alain Cantagrel, Thomas Barnetche, Bruno Fautrel, Nathalie Filippi, Cédric Lukas, Bernd Raffeiner, Maurizio Rossini, Yannick Degboé, Arnaud Constantin
Journal: Annals of the Rheumatic Diseases (2017)

To assess the risk of losing remission, low disease activity (LDA) or radiographic progression in the case of (1) discontinuing or (2) tapering doses of biological disease-modifying antirheumatic drugs (bDMARDs) compared with continuation of the initial treatment regimen in rheumatoid arthritis (RA) patients with remission or LDA.A systematic literature analysis was carried out through May 2017 on the PubMed, Embase, Cochrane and international congress databases, selecting controlled trials comparing bDMARDs discontinuation/tapering versus continuation in RA patients with remission or LDA. The meta-analysis assessed the risk ratio (RR) and 95% CI of losing remission or LDA and the risk of radiographic progression after (1) discontinuing and (2) tapering doses of bDMARDs versus continuing the initial treatment.The meta-analysis comparing bDMARDs discontinuation versus continuation performed on nine trials showed an increased risk of losing remission (RR (95% CI)=1.97(1.43 to 2.73), P<0.0001) or LDA (RR (95% CI)=2.24(1.52 to 3.30), P<0.0001) and an increased risk of radiographic progression (RR (95% CI)=1.09(1.02 to 1.17), P=0.01) in case of bDMARD discontinuation. The meta-analysis comparing bDMARDs tapering versus continuation performed on 11 trials showed an increased risk of losing remission (RR (95% CI)=1.23(1.06 to 1.42), P=0.006) but no increased risk of losing LDA (RR (95% CI)=1.02 (0.85 to 1.23), P=0.81) nor any increased risk of radiographic progression (RR (95% CI)=1.09(0.94 to 1.26), P=0.26) in case of bDMARD tapering.Discontinuation of bDMARDs leads to an increased risk of losing remission or LDA and radiographic progression, while tapering doses of bDMARDs does not increase the risk of relapse (LDA) or radiographic progression, even though there is an increased risk of losing remission.
Perceptions on the effect of physical activity on quality of life, overall survival, and fatigue in palliative cancer patients.
Authors: Karmugi Balaratnam, Graham McFarlane, Peter Selby, Shabbir Alibbhai, M. Catherine Brown, Jennifer M. Jones, Doris Howell, Dan Pringle, Wei Xu, Geoffrey Liu, Lawson Eng
Journal: Journal of Clinical Oncology (2017)

198 Background: Physical activity is an important lifestyle recommendation for all patients’ wellbeing. With better cancer treatments and palliative patients living longer, maintaining physical activity is becoming an important survivorship goal, even in the palliative setting. We assessed cancer patient’s perception of the effect of physical activity on their quality of life, overall survival, and fatigue. Methods: In a cross-sectional survey across all cancer sites, patient perception of the effect of physical activity on three outcomes: quality of life, overall survival, and fatigue. Palliative status was determined by chart review and primary oncologist assessments. Regression-based estimates of the odds ratios and confidence intervals (CI) described any differences in perception between palliative and non-palliative patients. Results: Of 1283 patients recruited, 1080 completed the entire survey; median (range) age was 58 (18-98) years; 54% were female; 15% were palliative. Palliative patients were less likely than non-palliative patients to believe that physical activity improved overall survival, with an odds ratio of 0.53 (95%CI 0.34-0.83; P = 0.006). Palliative patients were less likely to perceive that physical activity improved fatigue, with odds ratio 0.68 (95%CI: 0.47-0.97; P = 0.04). Although not statistically significant, palliative patients also perceived less of a positive effect of physical activity on quality of life with an odds ratio of 0.65 (95% CI 0.47-0.97; P = 0.12). Results were similar regardless of whether patients were asked to perceive the effect of physical activity on themselves or in the general cancer patient. Conclusions: Palliative patients were more likely to believe that physical activity did not improve their overall survival and fatigue compared to the curative counterparts. Also, there was no significant difference in the perception of the effect of physical activity on the quality of life among the two groups of cancer survivors. Since palliative patients are living longer, future research can focus on implementing exercise recommendations and following up so the actual benefits can be seen.
Ultrasound application in point of care by palliative medicine physicians: Initial experience of oncology palliative medicine consultation in two rural area hospitals in Costa Rica.
Authors: Karol Villalobos
Journal: Journal of Clinical Oncology (2017)

254 Background: Point of care Ultrasonography (POCUS)—that is ultrasonography performed and interpreted by the clinician at the bedside—is a method of clinical focused evaluation assisted by ultrasound equipment which gives the health provider in limited resources conditions, a prompt and accurate diagnosis for a limited number of pathologies. Development of portable ultrasound equipment with accessible technologies in terms of health investment, allows developing such practice in non-conventional resource-limited settings as patient homes. Our proposal is to show point of care ultrasonography (POCUS) experiences by two Palliative Care specialist doctors with in government-managed Social Security service (CCSS) in rural areas in Costa Rica. Methods: Limited diagnosis examinations were performed both at the hospital as well as at out of hospital sites in rural areas of Turrialba, and San Carlos, Costa Rica. Percutaneous procedures took place at the hospital following monitoring and aseptic standards, using two different units (Contec CMS600P2B, Phillips Clearvue 550). Results: Each brief case presented in this article shows effective Point of Care Ultrasound uses for patients with life-limiting conditions in resource-limited settings. Use of this technology by palliative medicine specialists in these cases helped patients and their families by accelerating right diagnosis, limiting unnecessary hospital transportation or by helping making safer procedures. Conclusions: Point of care ultrasound usage by palliative medicine specialists is an innovation breaking paradigms that has shown in our case to be a successful help as an evaluation strategy in a limited-resources rural environment, with a frail population.